Calcium dobesilate is a vasoactive drug with well-known effects on endothelial integrity, vascular wall permeability and blood viscosity. A clinical study demonstrated that serum thromboxane formation is significantly decreased by calcium dobesilate in patients suffering from peripheral vascular disease. Hence an in vitro study has been undertaken to determine the influence of calcium dobesilate on eicosanoid formation both by platelets and the arterial wall. Radio-thin-layer chromatography (RTLC) of human platelets does not show any influence of the drug on eicosanoid conversion in a dose range from 10 to 1000 micrograms/ml. By contrast, the vascular conversion of eicosanoids shows a dose-dependent trend towards a decrease in cyclooxygenase products. However, using the same doses, no effect is observed on vascular PGI2 formation in vitro, as assessed by means of the platelet aggregation bioassay and thus no inhibitory effect on cyclooxygenase of the arterial wall can be deduced. These laboratory findings provide no explanation for the clinical efficacy of calcium dobesilate and the diminution in serum thromboxane. A different mode of metabolic conversion of endogenous and exogenous arachidonic acid is suggested as explanation for these contradictory results.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Discovery of a potent, Kv7.3-selective potassium channel opener from a Polynesian traditional botanical anticonvulsant.
Commun Chem
October 2024
Bioelectricity Laboratory, Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
Plants remain an important source of biologically active small molecules with high therapeutic potential. The voltage-gated potassium (Kv) channel formed by Kv7.2/3 (KCNQ2/3) heteromers is a major target for anticonvulsant drug development.
View Article and Find Full Text PDFWhich dose of calcium dobesilate is more effective and safe in chronic venous insufficiency? Multicenter retrospective clinical trial.
Phlebology
September 2024
Department of Cardiovascular Surgery, Memorial Hospital, Ankara, Turkey.
Article Synopsis
- The study evaluated the effectiveness and safety of two dosages of calcium dobesilate (500 mg vs. 1000 mg) in patients with Chronic Venous Insufficiency (CVI) in CEAP classes C3-C4.
- A multicenter retrospective analysis monitored patient progress over 12 months, using scores and circumference measurements to gauge improvement.
- Results showed that the higher dosage (1000 mg) significantly improved symptom relief and reduced limb swelling compared to the lower dosage, indicating a potential benefit of using higher doses for managing advanced CVI.
Correction of negative-interference from calcium dobesilate in the Roche sarcosine oxidase creatinine assay using CuO.
Clin Chem Lab Med
January 2025
Clinical Laboratory, Minhang Hospital, 12478 Fudan University, Shanghai, Shanghai, China.
Study protocol for assessment of the efficacy of calcium dobesilate versus placebo on SARS-CoV-2 viral load in outpatients with COVID-19 (CADOVID study): a randomised, placebo-controlled, double-blind, monocentric phase II trial.
BMJ Open
May 2024
Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
Introduction: SARS-CoV-2 mainly infects respiratory endothelial cells, which is facilitated through its spike protein binding to heparan sulphate. Calcium dobesilate (CaD) is a well-established, widely available vasoactive and angioprotective drug interacting with heparan sulphate, with the potential to interfere with the uptake of SARS-CoV-2 by epithelial cells. The CADOVID trial aims to evaluate the efficacy and safety of CaD in reducing the SARS-CoV-2 viral load in non-hospitalised adult patients diagnosed with COVID-19, confirmed by a positive SARS-CoV-2 PCR, including its efficacy to reduce the impact of persistent COVID-19 symptoms.
View Article and Find Full Text PDFAssessment of the Tolerance of Dobenox Forte in Patients with Chronic Venous Disease.
Life (Basel)
March 2024
Department of Physiotherapy, School of Health Sciences in Katowice, Medical University of Silesia in Katowice, 40-752 Katowice, Poland.
This prospective, observational, multicenter study assessed the tolerance of Dobenox Forte, the first approved over-the-counter product containing calcium dobesilate, in 1795 outpatients with chronic venous disease (CVD) in daily clinical practice. In addition, the effectiveness (decrease in circumferences of a more affected limb at the ankle and middle part of the calf, and changes in the severity of CVD signs) was assessed. No adverse events related to use of the preparation were reported in a period of 64 ± 20 days.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!